IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 46219

In re patent application of
KISO et al.
Serial No. 09/857,695
Filed: June 8, 2001
For: THERAPEUTIC AGENTS FOR HYPERAMMONEMIA

Group Art Unit: 1623
Examiner: D. Khare

TRANSMITTAL OF RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an Response in the above-captioned application. The fee has been calculated as shown below. *(Small entity fees indicated in parentheses.)*

CLAIMS AS AMENDED						
(1)	(2)	(3)	(4)	(5)	(6)	(7)
	Claims Remaining After Amendment		**Highest Number Previously Paid For**	**Extra Claims**	**Rate**	**Fee**
Total Claims	18	-	20		18.00	**0**
(Small Entity)					*(9.00)*	
Independent claims	9	-	9		84.00	**0**
(Small Entity)					*(42.00)*	
Multiple Dependent	0	-	0	0	280.00	**0**
(Small Entity)					*(140.00)*	
Extension of Time	**One Month**		**Two Months**	**Three Months**		
Fee	$110		$400	$920		**$920.00**
(Small Entity)	*($55)*		*($200)*	*($460)*		**0**
Total						**$920.00**

The above fees are believed to be correct. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0687 under the above Attorney Docket Number for which purpose this paper is submitted in duplicate.

Respectfully submitted,

Date: **November 6, 2002**

Paul E. White, Jr.
Reg. No. 32,011
Tel. No. 202-261-1050
Fax No. 202-887-0336

Manelli Denison & Selter, PLLC
2000 M Street, N.W.
Suite 700
Washington, D.C. 20036-3307
202.261.1000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of
KISO, et al.

Group Art Unit: 1623

Appln. No.: 09/857,695

Examiner: D. Khare

Filed: June 8, 2001

Title: THERAPEUTIC AGENTS FOR HYPERAMMONEMIA

* * * * * *

November 6, 2002

AMENDMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

In response to the Office Action dated May 6, 2002, please amend the subject application as follows.

IN THE CLAIMS:

Please amend claims 3, 7, 8, 9, 10, 11 and 13-18 as follows (see the attached Appendix for the changes made to effect the below claims):

Claim 3. (Amended) The blood ammonia lowering agent according to claim 2, wherein said xylooligosaccharide contains at least 30 wt% of xylobiose

Claim 7. (Amended) The therapeutic agent of hyperammonemia according to claim 6, wherein said xylooligosaccharide contains at least 30 wt% of xylobiose.